# OnCo record paper-keynote-590-lancet-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-590-lancet-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-590-lancet-2021" ;
  schema:name "KEYNOTE-590: pembrolizumab plus chemotherapy for first-line treatment of advanced oesophageal cancer"@en ;
  schema:description "Adding pembrolizumab to cisplatin-fluorouracil lengthened survival in advanced oesophageal cancer of both histologies, most clearly in squamous cell carcinoma and in tumours with high PD-L1, establishing chemo-immunotherapy as the first-line standard."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-590-lancet-2021/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(21)01234-4>, <https://pubmed.ncbi.nlm.nih.gov/34454674/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(21)01234-4> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Sun JM, Shen L, Shah MA, et al." ;
  onco:cancers <https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/>, <https://onco.cc/cancers/oesophageal-adenocarcinoma/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:trials <https://onco.cc/trials/keynote-590/> ;
  onco:journals <https://onco.cc/journals/lancet/> .